文献速递真菌感染

新型隐球菌与格特隐球菌感染的流行病学与结局:国际队列研究

MSG07: An International Cohort Study Comparing Epidemiology and Outcomes of Patients With Cryptococcus neoformans or Cryptococcus gattii Infections.
PubMed 文献 · Clin Infect Dis · 2021-01-01

该回顾性队列纳入1995—2013年北美和澳大利亚5个中心709例培养确诊隐球菌病患者,比较新型隐球菌与格特隐球菌感染的流行病学、临床表现、治疗及结局。格特隐球菌患者诊断延迟更久、无基础疾病比例更高、肺部感染更常见;新型隐球菌患者中枢神经系统或血流感染更常见,12个月粗死亡率更高。

要点

  • 格特隐球菌感染更多见于无基础疾病者且以肺部感染为主。
  • 新型隐球菌感染更常累及中枢神经系统或血流,12个月粗死亡率更高。
  • 隐球菌病应进行菌种鉴定以判断流行病学模式并指导治疗。

核心结论

  • 隐球菌病在新型隐球菌与格特隐球菌之间存在基础疾病、感染部位和死亡率的差异,菌种鉴定对判断流行病学模式、指导治疗方案和预测临床进展与结局是必要的。

研究设计与样本

  • 回顾性队列研究,纳入1995—2013年北美和澳大利亚5个中心培养确诊的隐球菌病患者共709例,其中新型隐球菌452例、格特隐球菌257例。

主要发现

  • 格特隐球菌患者诊断时间较新型隐球菌患者延长(均值52.2天 vs 36.0天,P < .003)。
  • 格特隐球菌患者无基础疾病比例高于新型隐球菌患者(40.5% vs 10.2%,P < .0001)。
  • 肺部感染在格特隐球菌患者中更常见(60.7% vs 32.1%,P < .0001),中枢神经系统或血流感染在新型隐球菌患者中更常见(两者P ≤ .0001)。
  • 12个月粗死亡率在新型隐球菌患者中更高(28.4% vs 20.2%;比值比1.56[95%置信区间1.08-2.26])。

关键数值与推荐

  • 总体59%患者有中枢神经系统感染,肺部(42.5%)和血液(24.5%)为常见感染部位。
  • 中枢神经系统疾病接受两性霉素B联合氟胞嘧啶诱导治疗者占76.4%。
  • 患者平均年龄50.2岁,男性占61.4%,白人占52.3%。

临床怎么用

  • 对隐球菌病患者应进行菌种鉴定,以区分新型隐球菌与格特隐球菌的流行病学特征并指导治疗决策。
  • 格特隐球菌感染需注意肺部受累及无基础疾病人群,新型隐球菌感染需警惕中枢神经系统或血流受累及较高死亡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cryptococcosis due to Cryptococcus neoformans and Cryptococcus gattii varies with geographic region, populations affected, disease manifestations, and severity of infection, which impact treatment. METHODS: We developed a retrospective cohort of patients diagnosed with culture-proven cryptococcosis during 1995-2013 from 5 centers in North America and Australia. We compared underlying diseases, clinical manifestations, treatment, and outcomes in patients with C. gattii or C. neoformans infection. RESULTS: A total of 709 patients (452 C. neoformans; 257 C. gattii) were identified. Mean age was 50.2 years; 61.4% were male; and 52.3% were white. Time to diagnosis was prolonged in C. gattii patients compared with C. neoformans (mean, 52.2 vs 36.0 days; P < .003), and there was a higher proportion of C. gattii patients without underlying disease (40.5% vs 10.2%; P < .0001). Overall, 59% had central nervous system (CNS) infection, with lung (42.5%) and blood (24.5%) being common sites. Pulmonary infection was more common in patients with C. gattii than in those with C. neoformans (60.7% vs 32.1%; P < .0001). CNS or blood infections were more common in C. neoformans-infected patients (P ≤ .0001 for both). Treatment of CNS disease with induction therapy of amphotericin B and flucytosine occurred in 76.4% of patients. Crude 12-month mortality was higher in patients with C. neoformans (28.4% vs 20.2%; odds ratio, 1.56 [95% confidence interval, 1.08-2.26]). CONCLUSIONS: This study emphasizes differences in species-specific epidemiology and outcomes of patients with cryptococcosis, including underlying diseases, site of infection, and mortality. Species identification in patients with cryptococcosis is necessary to discern epidemiologic patterns, guide treatment regimens, and predict clinical progression and outcomes.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Baddley JW, Chen SC, Huisingh C, et al. MSG07: An International Cohort Study Comparing Epidemiology and Outcomes of Patients With Cryptococcus neoformans or Cryptococcus gattii Infections. Clin Infect Dis. 2021. PMID: 33772538. doi:10.1093/cid/ciab268

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。